Short Interest in Burning Rock Biotech Limited (NASDAQ:BNR) Drops By 6.6%

Burning Rock Biotech Limited (NASDAQ:BNR) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 60,500 shares, a decrease of 6.6% from the December 15th total of 64,800 shares. Based on an average daily volume of 26,300 shares, the short-interest ratio is presently 2.3 days. Currently, 0.7% of the company’s stock are short sold.

Burning Rock Biotech Price Performance

BNR traded up $0.25 during midday trading on Friday, hitting $6.75. 308 shares of the company’s stock traded hands, compared to its average volume of 7,089. The company has a market cap of $69.07 million, a PE ratio of -2.25 and a beta of 0.55. Burning Rock Biotech has a one year low of $2.62 and a one year high of $9.80. The stock’s fifty day simple moving average is $6.15 and its 200-day simple moving average is $5.29.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Burning Rock Biotech stock. SkyView Investment Advisors LLC acquired a new stake in Burning Rock Biotech Limited (NASDAQ:BNR) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned approximately 0.10% of Burning Rock Biotech as of its most recent filing with the SEC. 30.03% of the stock is currently owned by institutional investors and hedge funds.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.